ACOG: Alpha Cognition Inc. Future Price to Earnings
Drug development for brain pathologies at Alpha Cognition (ACOG) relies on patent protection and strict regulatory oversight, which curbs the expansion of generic alternatives. This price chart confirms a current P/E multiple of 0.00. The business is currently transitioning to the commercialization of its primary Alzheimer's disease treatment, although high dependence on a single product creates significant market risks during the sales rollout.
Financial and market metric breakdowns for Alpha Cognition Corp (ACOG)
- stock value and consensus price forecast:
- market capitalization information:
- balance sheet equity data:
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Alpha Cognition|ACOG - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Alpha Cognition|ACOG - Company Total Debt|Debt to Book Capitalization Ratio Alpha Cognition Inc|ACOG - Long-Term Debt|Company Short-Term Debts Alpha Cognition|Quick Liquidity alphacognition.com
- earnings and market ratios statistics:
ACOG - Company Profit|Projected Future Earnings Alpha Cognition|ACOG - Business Payback Period|Projected Price to Earnings Alpha Cognition|ACOG - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Alpha Cognition Inc|ACOG - Operating income before deduction of amortization|Earnings per share for the last twelve months Alpha Cognition|ACOG - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months alphacognition.com|ACOG - Earnings per share growth this year|Earnings growth forecast for next year Alpha Cognition
Fundamental company analysis:ACOG Alpha Cognition Inc.
Alpha Cognition is developing innovative treatments for Alzheimer's disease for the global neurology market. The forward P/E is calculated as the ratio of the current share price to the projected earnings for the future period. This multiple measures market expectations regarding business scaling rates and the efficacy of new drugs. A high premium confirms investor confidence in growth but increases the risk of a correction. By analyzing the forward P/E valuation dynamics of Alpha Cognition, the strategist determines the sustainability of its capitalization.
Competitors of Alpha Cognition (ACOG)
Future Price to Earnings Biogen (BIIB)|Future Price to Earnings NBIX (Neurocrine)|Future Price to Earnings Regencell RGC|AXSM (Axsome Corp) - Price to Expected Earnings Ratio|ACADIA Pharmaceuticals - Forward P/E Multiple|Future Price to Earnings Multiple XENE (xenon-pharma.com)|VKTX: Forward P/E Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Forward P/E Multiple|Projected Price to Earnings CPRX|DNLI: Future Price to Earnings Multiple|Forward P/E Multiple HRMY|Projected Price to Earnings biohavenpharma.com BHVN|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|Trevi Therapeutics Inc (TRVI) - Projected Price to Earnings Ratio|Praxis Medicines - Forward P/E Multiple|Forward Price to Earnings Multiple Anavex Life Sciences Corp (AVXL)|CeriBell, Inc. (CBLL) - Future Price to Earnings|Price to Future Earnings Ratio PRTA|ALEC (Alector Inc.) - Forward P/E Multiple|Annexon Biosciences (ANNX) - Market Cap to Projected Earnings|Projected Price to Earnings OMER (Omeros Corporation)|Market Cap to Future Earnings Ratio NGNE|Forward P/E Multiple ACIU (AC Immune)|Market Cap to Projected Earnings voyagertherapeutics.com (VYGR)|NMRA - Future Price to Earnings|Projected Price to Earnings Ratio Scilex Holding|Tevogen Bio Holdings, Inc. (TVGN) - Future Price to Earnings|Price to Future Earnings Ratio CGTX|IKT (Inhibikase Therapeutics) - Forward P/E Multiple|Forward P/E Multiple cassavasciences.com|Forward P/E Multiple ASRT|Projected Price to Earnings coyatherapeutics.com COYA|Future Price to Earnings Vistagen VTGN|Ovid Therapeutics Inc (OVID) - Projected Price to Earnings Ratio|Acumen Pharmaceuticals - Forward P/E Multiple|Forward Price to Earnings Multiple cervomed.com (CRVO)|alteritytherapeutics.com (ATHE) - Future Price to Earnings|Price to Future Earnings Ratio CLNN|PEPG (PepGen Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Jupiter Neurosciences, Inc. JUNS|Projected Price to Earnings RLMD (Relmada Therapeutics)|Forward P/E Multiple annovisbio.com (ANVS)|Future Price to Earnings Grace Therapeutics GRCE|Future Price to Earnings Multiple AIFF|KLTO - Future Price to Earnings|Projected Price to Earnings Ratio NeuroSense Therapeutics|RVPH: Forward P/E Multiple|MetaVia (MTVA) - Forward P/E Multiple|Future Price to Earnings NeurAxis|Future Price to Earnings HSDT|Future Price to Earnings Passage Bio, Inc. (PASG)|NEUP: Price to Expected Earnings Ratio|Forward P/E Multiple NERV (Minerva Neurosciences)|Future Price to Earnings Multiple ATHA|Addex Therapeutics Ltd - Forward P/E Multiple|ALZN - Forward P/E Multiple|CYCN (cyclerion.com) - Projected Price to Earnings|Protagenic Therapeutics, Inc. - Future Price to Earnings Multiple|KTTA (Pasithea Therapeutics Corp) - Forward P/E Multiple|Projected Price to Earnings Cortigent Medical (CRGT)|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics, Inc)|Forward Price to Earnings Multiple Chromocell|ELYM - Future Price to Earnings|ITCI (Intra-Cellular Therapies) - Price to Future Earnings Ratio|LBPH: Forward P/E Multiple|MRNS - Market Cap to Projected Earnings|Projected Price to Earnings NKGN|NRBO (NeuroBo Pharma) - Market Cap to Future Earnings Ratio|Forward P/E Multiple SAGE|Market Cap to Projected Earnings synaptogen.com|Future Price to Earnings Trevena TRVN|Vigil Neuroscience Inc. (VIGL) - Projected Price to Earnings Ratio|WENA - Future Price to Earnings|CERE (Cerevel Corp) - Price to Future Earnings Ratio
